Synaptogenix (TAOX) Competitors

Cardiol Therapeutics presently has a consensus target price of $8.50, suggesting a potential upside of 541.51%. Given Cardiol Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Cardiol Therapeutics is more favorable than Synaptogenix.

12.5% of Cardiol Therapeutics shares are held by institutional investors. Comparatively, 10.3% of Synaptogenix shares are held by institutional investors. 5.3% of Cardiol Therapeutics shares are held by insiders. Comparatively, 2.7% of Synaptogenix shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Cardiol Therapeutics has a beta of 0.77, suggesting that its stock price is 23% less volatile than the S&P 500. Comparatively, Synaptogenix has a beta of 1.49, suggesting that its stock price is 49% more volatile than the S&P 500.

In the previous week, Cardiol Therapeutics' average media sentiment score of 0.00 equaled Synaptogenix'saverage media sentiment score.

Synaptogenix's return on equity of -193.08% beat Cardiol Therapeutics' return on equity.

Cardiol Therapeutics has higher earnings, but lower revenue than Synaptogenix. Cardiol Therapeutics is trading at a lower price-to-earnings ratio than Synaptogenix, indicating that it is currently the more affordable of the two stocks.

Tenaya Therapeutics has a consensus target price of $4.00, suggesting a potential upside of 423.56%. Given Tenaya Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Tenaya Therapeutics is more favorable than Synaptogenix.

10.3% of Synaptogenix shares are owned by institutional investors. Comparatively, 90.5% of Tenaya Therapeutics shares are owned by institutional investors. 2.7% of Synaptogenix shares are owned by company insiders. Comparatively, 48.7% of Tenaya Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Synaptogenix has a beta of 1.49, suggesting that its share price is 49% more volatile than the S&P 500. Comparatively, Tenaya Therapeutics has a beta of 2.77, suggesting that its share price is 177% more volatile than the S&P 500.

In the previous week, Tenaya Therapeutics had 2 more articles in the media than Synaptogenix. MarketBeat recorded 2 mentions for Tenaya Therapeutics and 0 mentions for Synaptogenix. Tenaya Therapeutics' average media sentiment score of 0.51 beat Synaptogenix's score of 0.00 indicating that Tenaya Therapeutics is being referred to more favorably in the news media.

Tenaya Therapeutics' return on equity of -85.20% beat Synaptogenix's return on equity.

Synaptogenix has higher revenue and earnings than Tenaya Therapeutics. Tenaya Therapeutics is trading at a lower price-to-earnings ratio than Synaptogenix, indicating that it is currently the more affordable of the two stocks.

Synaptogenix has a beta of 1.49, suggesting that its share price is 49% more volatile than the S&P 500. Comparatively, InflaRx has a beta of 2.42, suggesting that its share price is 142% more volatile than the S&P 500.

InflaRx's return on equity of -80.51% beat Synaptogenix's return on equity.

Synaptogenix has higher revenue and earnings than InflaRx. InflaRx is trading at a lower price-to-earnings ratio than Synaptogenix, indicating that it is currently the more affordable of the two stocks.

InflaRx has a consensus target price of $5.80, suggesting a potential upside of 195.17%. Given InflaRx's stronger consensus rating and higher probable upside, analysts plainly believe InflaRx is more favorable than Synaptogenix.

10.3% of Synaptogenix shares are owned by institutional investors. Comparatively, 42.4% of InflaRx shares are owned by institutional investors. 2.7% of Synaptogenix shares are owned by company insiders. Comparatively, 16.3% of InflaRx shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, InflaRx had 8 more articles in the media than Synaptogenix. MarketBeat recorded 8 mentions for InflaRx and 0 mentions for Synaptogenix. InflaRx's average media sentiment score of 0.56 beat Synaptogenix's score of 0.00 indicating that InflaRx is being referred to more favorably in the news media.

Synaptogenix has a beta of 1.49, suggesting that its share price is 49% more volatile than the S&P 500. Comparatively, Galectin Therapeutics has a beta of 0.45, suggesting that its share price is 55% less volatile than the S&P 500.

Galectin Therapeutics' return on equity of 0.00% beat Synaptogenix's return on equity.

Synaptogenix has higher revenue and earnings than Galectin Therapeutics. Galectin Therapeutics is trading at a lower price-to-earnings ratio than Synaptogenix, indicating that it is currently the more affordable of the two stocks.

Galectin Therapeutics has a consensus target price of $11.00, suggesting a potential upside of 402.28%. Given Galectin Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Galectin Therapeutics is more favorable than Synaptogenix.

10.3% of Synaptogenix shares are owned by institutional investors. Comparatively, 11.7% of Galectin Therapeutics shares are owned by institutional investors. 2.7% of Synaptogenix shares are owned by company insiders. Comparatively, 52.6% of Galectin Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Synaptogenix's average media sentiment score of 0.00 equaled Galectin Therapeutics'average media sentiment score.